




























Potential role of tumor suppressors p53 and 
WWOX/WOX1 in aging 
 
In year 2000, we and two other groups have 
independently discovered a candidate tumor suppressor, 
named WW domain-containing oxidoreductase (design-
nated WWOX, FOR, or WOX1) [1-7; reviews]. Human 
WWOX  gene is mapped to a common fragile site on 
chromosome ch16q23.3-24.1. Alteration of human 
WWOX  gene has been found in breast, prostate and 
many types of cancers. WWOX/WOX1 possesses func-
tional domains, including a nuclear localization seq-
uence (NLS), two N-terminal WW domains (containing 
conserved tryptophan residues) and a C-terminal short-
chain alcohol dehydrogenase/reductase (SDR) domain. 
The WW domain participates in molecular interactions, 
signaling and apoptosis [1-7]. Whether SDR domain 
has an  oxidoreductase  activity  remains  to  be   
established. There is a mitochondria-targeting segment 
in the SDR domain, which allows relocation of 
WWOX/WOX1 to the mitochondria [1-3,8].  Also, sex  
steroid  hormones estrogen  and  androgen  may  interact 
with an N-S-Y-Kmotif in the SDR domain that all- 
































Over the past 10 years of global research efforts, a big 
picture regarding the functional roles of WWOX/ 
WOX1 has been emerging. Areas of interests are           
the critical involvement of WWOX/WOX1 in 1) 
apoptotic and stress responses in vivo and in vitro [1-
3,7], 2) regulation of embryonic and tumor devel-
opment and postnatal survival in vivo [6,7], 3) 
signaling and regula-tion of gene transcription [1-3,7], 
4) normal physiology and metabolism [9-13], and 4) 
neural development, damage and degeneration (e.g. 
Alzheimer’s disease) in vivo [14-19]. 
 
WWOX/WOX1 is  known   to  increase  the   cyto-
toxic  function  of  tumor  necrosis  factor  (TNF)             
in killing cancer cells [1-3,7,8]. Ectopically expres-   
sed SDR domain is shown to increase TNF 
cytotoxicity by significant suppression of the 
expression of apoptosis inhibitors Bcl-2 and Bcl-xL     
by  >85%,  but  increase  in  the  expression  of              
pro-apoptotic p53 by ~200% [8]. Accordingly, 
transiently overexpressed SDR domain induces 
apoptosis.  Overexpressed WW domains also induce 
apoptosis of cancer cells via a different mech-           
anism, in which caspase activation was not shown  [8]. 
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in aging [20-22]. WWOX/WOX1 and p53 are partners 
in signaling and apoptosis [1-3,7,8]. Participation of 
WWOX/WOX1 in p53-regulated cellular aging is 
likely. In response to stress stimulation, WWOX/ 
WOX1 becomes phosphorylated at tyrosine 33 and 
relocates to the mitochondria and nuclei to induce 
apoptosis both in vivo and in vitro [1-3,8,14-18]. p53 
also relocates to the mitochondria under apoptotic 
stress [23,24]. p53 relays many routes of signal 
pathways [25], and WWOX/WOX1 physically inter-
acts with p53 and increases its stability in vivo [26]. 
That is, in the absence of WWOX/WOX1, p53 
becomes susceptible to ubiquitin/proteasome-mediated 
degradation. Activated WWOX/WOX1 with phos-
phorylation at Tyr33 binds activated p53 with Ser46 
phosphorylation [26]. Cumulative evidence shows that 
both activated WWOX/WOX1 and p53 act in a syn-
ergistic manner in promoting apoptosis [1,2,7,8,15-
18,26], suggesting that p53 and WWOX/WOX1 are 
partners in orchestrating aging probably via the 
mitochondrial pathway. 
 
Zfra participates in the TNF signaling 
 
To identify the possible presence of a common 
inhibitor of WWOX/WOX1 and p53, we carried out 
yeast two-hybrid cDNA library screen and identified a 
31-amino-acid WOX1- binding protein, named Zfra 
(zinc finger-like protein that regulates apoptosis) [27]. 
The amino acid sequence of Zfra is “MSSRRSSSCK 
YCEQDFRAHT QKNAATPFLA N”.  Structurally, 
Zfra is homologous to the family of C2H2 type zinc 
finger proteins. Zfra may be considered as the smallest 
member of the zinc finer protein family. Zfra poss-
esses 2 cysteines, suggesting that it may undergo self-
polymerization in vivo. Serine 8 (Ser8) is a conserved 
phosphorylation site. Overly expressed Zfra induces 
apoptosis in many types of cancer cells, whereas 
alteration of Ser8 abolishes its apoptotic function [28]. 
The induced apoptosis involves appearance of flip-
flopped phosphatidylserine on the cell surface, nuclear 
condensation and internucleosomal DNA fragment-
ation [27-29]. 
 
The abundance of Zfra is very low; however, it is 
inducible under stress conditions (e.g. UV irradiation). 
Majority of the zinc finger proteins are capable of 
interacting with DNA and RNA to control gene tran-
scription especially during embryogenesis, suggesting 
that Zfra may possess gene regulatory functions by 
binding with DNA and RNA. 
 
Due  to  its small in size, Zfra physically interacts with   
many proteins in the TNF signaling [27,28]. Also, it 
binds distinct sites at different domains in a single 
protein [28]. For example, Zfra binds to the N-terminal 
first WW domain and the C-terminal SDR domain of 
WOX1. Upregulation of TNF and inflammatory cyto-
kines is shown during normal or pathogenic aging 
processes [30]. Depending upon the extent of express-
ion, Zfra either enhances or blocks the cytotoxic 
function of TNF [27,28]. TNF instigates both cell 
survival and apoptosis pathways. In the TNF signaling, 
TNF binds cognate membrane receptors (TNF receptor 
type I and II) for recruiting death domain proteins 
TRADD, FADD and RIP to form a death inducing 
signaling complex (DISC) [31,32]. Caspase 8 is then 
bound to the DISC and becomes activated for 
executing apoptosis at both the mitochondrial and 
nuclear levels. Supporting evidence shows that poly-
ubiquitin coating of RIP and death domain proteins is 
needed to block the apoptosis cascade and simul-
taneous initiate the NF-κB survival pathway [31-34]. 
 
We determined that TNF increases the expression of 
Zfra and enhances its binding with TRADD at the 
plasma membrane [27,28]. We suspect that upon 
induction by TNF or Fas ligand, the overexpressed 
Zfra, together with TRADD and FADD, overrides the 
protective effect of polyubiquitinated RIP and thereby 
induces apoptosis. This likely scenario remains to be 
established. 
 
Zfra is a negative regulator of WOX1, p53 and 
JNK1 
 
Zfra binds downstream proteins in the TNF signaling. 
TNF induces the binding of Zfra with activated 
WOX1, JNK1, and NF-κB [27,28]. Zfra binds to the 
N-terminal first WW domain and the C-terminal SDR 
domain of WOX1. Without phosphorylation of Tyr33 
in the first WW domain, Zfra could not interact with 
WOX1 [28], suggesting that phospho- Tyr33 provides 
an accessible structural motif or site for Zfra binding. 
This binding blocks the apoptotic function of WOX1. 
By the same token, Zfra interacts with activated p53 
with phosphorylation at Ser46 and inhibits the p53-
mediated growth suppression and apoptosis [28]. 
Ser46 phosphorylation in p53 appears to be critical for 
its apoptotic function [26,35,36]. Zfra also binds JNK1 
and restricts its activity [28]. It appears that transiently 
overexpressed Zfra sequesters WOX1, NF-κB, p53, 
JNK1 and ERK in the cytoplasm, thereby blocking 
their transcriptional function and others. The first WW 
domain of WOX1 alone is sufficient to drive the 
transcriptional activation of the NF-κBresponsive 
element [18]. Sequestered WOX1 in the cytoplasm is 
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A role of Zfra in the nucleus 
 
Many C2H2 zinc fingers proteins are involved in the 
regulation of gene transcription, growth suppression, 
and/or apoptosis [37-39]. Nuclear localization of these 
proteins is essential for their functions. Supporting data 
shows that Zfra targets both nuclei and mitochondria for 
controlling cell growth and apoptosis [27,28]. For 
example, UV irradiation upregulates the expression of 
Zfra, and the protein becomes phosphorylated at Ser8 
and then relocates to the nucleus [28,29] (Route 1; 
Figure 1). That is, phospho-Zfra is found accumulated 
in the nucleus. Ser8 phosphorylated-Zfra is essential in 
inducing apoptosis probably starting at the nuclear 
level. Without Ser8 phosphorylation, no apoptosis 
occurs [27-29]. 
 
The specific threonine/serine kinase(s), which 
phosphorylates Zfra, is unknown and remains to be 
identified. A likely candidate for phosphorylating Zfra 
is JNK1. JNK1 plays a central role in the MAPK 
signaling, and it integrates many routes of signaling 
pathways [40]. TNF and UV light, for instance, causes 
JNK1 activation and induces the complex formation of 
Zfra and JNK1. Whether activated JNK1 phosphor-
ylates Zfra remains to be determined. Alternatively, 
Zfra may be able to stabilize and induce constitutive 
JNK1 activation, or cause rapid JNK1 turnover. 
 
Interestingly, phospho-Zfra undergoes rapid de-
phosphorylation and degradation, suggesting that Zfra 
may affect the functional activation and turnover of its 
binding proteins. During UV irradiation, Zfra is shown 
to physically interact with activated p53 and WOX1. 
That is, UV induces the de novo formation of the Zfra-
p53-WOX1 complex for relocating to the nuclei. 
Whether the endogenous Zfra blocks the apoptotic 
function of p53 and WOX1 remains to be determined. 
 
Zfra executes mitochondrial apoptosis on its own 
manner 
 
Zfra exhibits a unique function in modulating 
mitochondrial apoptosis. When cells are exposed to 
inducers of mitochondrial pathway of apoptosis (e.g. 
staurosporine or betulinic acid), Zfra becomes 
phosphorylated at Ser8 and relocates to the mito-
chondria [29]. Alteration of Ser8 to Gly8 abolishes Zfra 
relocation to the mitochondria. At the mitochondrial 
level, Zfra downregulates the expression of apoptosis 
inhibitor Bcl-2 and Bcl-xL (Route 2, Figure 1). Notably, 
this effect does not result in cytochrome c release. In the 
meantime, Zfra causes dissipation of mitochondrial 
membrane permeability, thereby leading to eventual 
chromosomal DNA fragmentation and cell death.  
 
Both Bcl-2 and Bcl-xL are potent inhibitors of the 
mitochondrial apoptosis [41-44]. They prevent the loss 
of mitochondrial membrane potential and suppress 
cytochrome c release. Of particular note is that Zfra 
suppresses the expression of Bcl-2 and Bcl-xL, but fails 
to cause cytochrome c release, which is very unusual 
and intriguing. Cytochrome c release from the 
mitochondria is a hallmark event in apoptosis. A likely 
scenario is that Zfra directly binds cytochrome c and 
blocks its release from the mitochondria (Route 3, 
Figure 1). 
 
Suppression of Bcl-2 and Bcl-xL expression by Zfra 
may be due to its ability in interacting with DNA and 
RNA for regulating gene transcription during cell 
growth and death, just like the functions of many zinc 
finger proteins [37-39]. Indeed, by “mRNA immuno-
precipitation” using specific Zfra antibodies, Zfra binds 
quite a few mRNA molecules. How Zfra modifies the 
translation of mRNA to protein requires further 
investigation. 
 
Normally, release of proapoptotic proteins (e.g. 
cytochrome c and Smac/DIABLO) in the intermem-
brane space of mitochondria requires leakage of outer 
mitochondrial membrane. Bcl-2 and Bcl-xL provide a 
homeostatic control against the pore forming activity of 
Bax and Bak [41-45]. Under certain circumstance, 
cytochrome c release is not essential for leading to 
apoptosis such as in Fas-induced caspase activation and 
apoptosis [46]. Apoptosis may occur in the absence of 
cytochrome c release from the mitochondria and 
accumulation in the cytosol [47]. In addition, dis-
sipation of mitochondrial membrane potential is not 
essential for DNA fragmentation [48]. 
 
Zfra induces mitochondrial membrane potential 
dissipation 
 
Although Zfra may block cytochrome c release, 
overexpressed Zfra causes mitochondrial membrane 
potential (MMP) dissipation [29]. Alteration of lipids 
and cytosolic proteins on the gating properties of 
voltage-dependent anion channel (VDAC) may play an 
important role in permeabilization of mitochondrial 
outer membrane at the early stage of apoptosis [43]. 
Also, activated tBid and Bax increase the pore size of 
mitochondrial VDAC for cytochrome c release. This 
effect may be blocked by cyclic AMP-dependent 
protein kinase A (PKA) in the presence of ATP. 
Blocking of cytochrome c release by Zfra may be due to 
   










































its interaction with VDAC (Route 3, Figure 1). 
 
Zfra controls p53- and WOX1-regulated mitochon-
drial apoptosis 
 
Numerous proteins are shown to relocate to the 
mitochondria during apoptosis. WOX1, p53 and Zfra 
are known molecules, which participate in apoptosis via 
the mitochondrial pathway. Whether relocation of 
WOX1, p53 and Zfra occurs as a tri-molecular complex 
is not known. Nonetheless, there is a close functional 
relationship  among  these  proteins.  For  example,       











































(Routes 4 and 5, Figure 1). Tyr33-phosphorylated or 
activated WOX1 binds to the proline-rich region and 
phospho-Ser46 of p53, and both proteins induce 
apoptosis synergistically [8,26]. Knockdown or func-
tional suppression of WOX1 by antisense mRNA, small 
interfering RNA, or dominant negative leads to 
decreased stability of p53 and apoptotic function [26]. 
Overexpressed Zfra sequesters WOX1 and p53 in the 
cytoplasm. Interestingly, introduction of Ser8-mutated 
or inactivated Zfra in cells spontaneously induces 
translocation of WOX1 and p53 to the mitochondria, 
suggesting that Ser8 is crucial for Zfra in control-         




Figure 1. Zfra in the mitochondrial pathway of apoptosis.  UV light induces Zfra phosphorylation (pZfra) at Ser8 and 
translocation to the nuclei (Route 1). Zfra rapidly undergoes de-phosphorylation and degradation in the nuclei [29]. However, in response 
to stimuli for the mitochondrial pathway of apoptosis, Zfra becomes Ser8-phosphorylated and relocates, along with p53 and WOX1, to 
the mitochondria. Ectopic Zfra significantly downregulates Bcl-2 and Bcl-xL (Route 2), blocks cytochrome c release by interacting with 
voltage-dependent anion channel (VDAC) (Route 3), and yet induces dissipation of mitochondrial membrane potential [29]. 
Alternatively, Zfra probably interacts with cytochrome c to block its release from the mitochondria. Zfra binds and blocks the apoptotic 
function of WOX1 (Route 4). Overexpressed WOX1 induces cytochrome c release (Route 5) [29]. By the same token, Zfra blocks 
apoptotic function of p53 in the mitochondria. 
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WOX1 is significantly downregulated in the hippo-
campi of patients with Alzheimer’s disease [14]. In 
vitro analysis reveals that downregulation of WOX1 
leads to tau  hyperphosphorylation in neuroblastoma 
cells, which positively correlates with the increased tau 
hyperphosphorylation in vivo [14]. It appears that in 
addition to tau, many proteins may undergo aggregation 
in the absence of WOX1 in vitro. Whether this occurs 
with Zfra is unknown. Zfra possesses 2 cysteines, and 
this allows Zfra to readily undergo polymerization. 
Binding of Zfra with WOX1 would prevent Zfra self-
polymerization. Conceivably, Zfra is likely to play a 
role in neurodegeneration. 
 
Zinc finger proteins directly or indirectly affect cellular 
aging. For example, as a p53 target gene, Wig-1 
encodes a zinc finger protein for binding to double-
stranded RNA and enhancing p53 mRNA stability via 
interacting with the 3'UTR in a positive feedback loop 
[49]. Defective in zinc finger protein in controlling 
cellular DNA repair processes may link to several 
human neurological disorders, such as ataxia with 
oculomotor apraxia 1 and spinocerebellar ataxia with 
axonal neuropathy 1 [50]. Additionally, zinc finger 
mproteins participate in degenerative skeletal disorders 
in an increasingly aging population [51] and cognitive 
impairment [52]. The functional role of Zfra in 
controlling aging processes is of interest for 
investigation. 
 
In summary, Zfra is a 31-amino-acid zinc finger-like 
protein. Zfra regulates cell death in the pathway of 
tumor necrosis factor (TNF) by physically interacting 
with receptorassociated adaptor TRADD and down-
stream NF-κB, JNK1, and WOX1 [28]. Remarkably, 
transiently overexpressed Zfra inhibits Bcl-2/Bcl-xL 
expression without causing cytochrome c release from 
the mitochondria, and induces loss of mitochondrial 
membrane permeability for leading to apoptosis [29]. 
While the underlying mechanism is largely unknown, 
Zfra may undergo self-association in response to stress 
stimuli and suppresses the function of NF-κB, WOX1, 
p53 and ERK. These observations suggest a role of Zfra 
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